'%2F%3E%3Cpath%20d%3D'M11%205H21M13.5%205V11.6A8.5%208.5%200%201%200%2018.5%2011.6V5'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'3.4'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Cpath%20d%3D'M10.6%2019.6L13.9%2021.8L17.6%2018.4L21.4%2020.4'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'2.6'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Ccircle%20cx%3D'17.6'%20cy%3D'18.4'%20r%3D'2.6'%20fill%3D'%23fff'%2F%3E%3C%2Fsvg%3E){kind=small}
Accretion Pharmaceuticals Limited
ACCPL (NSE) · ACCPL (BSE 213326) · ISIN INE0T8T01010 · Pharmaceuticals · listed 2025
Open the full company file Every section, filings and your notes, in the app.
Quarterly results
No quarterly results stored for this company yet.
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 31 Mar 2026 standalone | ₹54.71 cr | ₹12.32 cr | ₹76.66 cr |
| 30 Sep 2025 standalone | ₹46.58 cr | ₹7.86 cr | ₹59.07 cr |
| 31 Mar 2025 standalone | ₹15.29 cr | ₹14.1 cr | ₹39.87 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 73.52% | 0.17% | 3.65% | 26.48% |
Latest filings
- Annual Report FY2025-26 (New) 3 August 2026 · NSE
- Accretion Pharmaceuticals Limited has informed the Exchange about Investor Presentation 15 May 2026 · NSE
- Accretion Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 15, 2026, titled "Company Delivers Robust Performance in H2 FY26: Revenue up 18.24% YoY and EBITDA up 4. 15 May 2026 · NSE
- Accretion Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. 8 May 2026 · NSE
- Accretion Pharmaceuticals Limited has informed the Exchange about Transcript 22 November 2025 · NSE
Other companies in Pharmaceuticals
- Lupin Limited
- Sun Pharmaceutical Industries Limited
- Cipla Limited
- Dr. Reddy's Laboratories Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Aurobindo Pharma Limited
- Divi's Laboratories Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 30 September 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.